News
inflammatory bowel disease

Sanofi, CytoReason expand AI deal into IBD

Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver artificial intelligence (AI) for drug discovery and development in the fiel

News
mycamine_pack_shot

Sandoz bulks up with Mycamine ahead of spin-off

With a separation from parent company Novartis now confirmed, Sandoz has moved to strengthen its revenue base with the acquisition of global rights to mainstay antifungal drug Mycamine from

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

Partner Content